13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001937964
Total reported value
$541.9M
$541.9M
44 檔
45.8%
In Q3 2024, Artia Global Partners LP's U.S. equity holdings reached a combined market value of $541.9M, distributed across 44 disclosed stock positions.
Artia Global Partners LP executed strategic sector rebalancing during Q3 2024, establishing 7 new positions while fully exiting 9 holdings and trimming 4 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 25.98% | -7.04% | EXIT | |
| 2 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 24.07% | — | +7.23% | |
| 3 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 9.20% | +0.12% | +17.64% | |
| 4 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 4.32% | — | — | |
| 5 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 4.05% | — | — | |
| 6 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.78% | -0.46% | EXIT | |
| 7 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.62% | — | — | |
| 8 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 2.40% | — | — | |
| 9 | PCVX | Vaxcyte Inc | Stock-Other | 2.38% | — | — | |
| 10 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.24% | +0.74% | — | |
| 11 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 2.15% | — | — | |
| 12 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.53% | +0.04% | — | |
| 13 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.41% | — | — | |
| 14 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.19% | +3.98% | — | |
| 15 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.17% | — | — | |
| 16 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.17% | — | +13.61% | |
| 17 | ✓ | Merus N V | Stock-Other | 1.09% | — | +59.80% | |
| 18 | INSM | Insmed Inc | Stock-Healthcare | 1.05% | -18.15% | -0.93% | |
| 19 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.70% | — | — | |
| 20 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.64% | — | -46.64% | |
| 21 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.54% | — | +15.81% | |
| 22 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.47% | — | — | |
| 23 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.47% | — | — | |
| 24 | NUVL | Nuvalent Inc-a | Stock-Other | 0.43% | +0.01% | — | |
| 25 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.43% | -0.04% | — | |
| 26 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.35% | — | — | |
| 27 | EYPT | Eyepoint Inc | Stock-Other | 0.34% | +0.04% | +53.99% | |
| 28 | CRL | Charles River Laboratories | Stock-Healthcare | 0.34% | — | -8.69% | |
| 29 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.33% | -0.06% | -51.22% | |
| 30 | KROS | Keros Therapeutics Inc | Stock-Other | 0.32% | — | — | |
| 31 | KURA | Kura Oncology Inc | Stock-Other | 0.30% | — | — | |
| 32 | ASND | Ascendis Pharma A/S | Stock-Other | 0.30% | -0.81% | EXIT | |
| 33 | ANNX | Annexon Inc | Stock-Other | 0.28% | — | +16.78% | |
| 34 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.27% | — | +137.00% | |
| 35 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.26% | — | — | |
| 36 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.25% | — | — | |
| 37 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.25% | -0.08% | — | |
| 38 | ALEC | Alector Inc | Stock-Other | 0.25% | — | — | |
| 39 | IRON | Disc Medicine Inc | Stock-Other | 0.18% | — | — | |
| 40 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.16% | — | — | |
| 41 | ✓ | Acelyrin Inc | Stock-Other | 0.13% | — | — | |
| 42 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.09% | — | — | |
| 43 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.09% | — | — | |
| 44 | QTTB | Q32 Bio Inc | Stock-Other | 0.06% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | +9.8% | +16.20% | Add |
| 2 | NVO | Novo-nordisk A/s-spons Adr | +5% | +7.23% | Add |
| 3 | VKTX | Viking Therapeutics Inc | +4.6% | +17.64% | Add |
| 4 | SLNOEUR | Soleno Therapeutics Inc | +3% | +190.63% | Add |
| 5 | ITCIEUR | Intra-cellular Therapies Inc | +1.5% | — | Unchanged |
| 6 | PCVX | Vaxcyte Inc | +1.3% | — | Unchanged |
| 7 | RVMD | Revolution Medicines Inc | +1.2% | NEW | New buy |
| 8 | AZNN | Astrazeneca Plc-spons Adr | +1.2% | — | Unchanged |
| 9 | ARGX | Argenx Se - Adr | +1% | — | Unchanged |
| 10 | ALNY | Alnylam Pharmaceuticals Inc | +1% | — | Unchanged |
| 11 | VRNA | Verona Pharma PLC - Adr | +0.8% | +13.61% | Add |
| 12 | AXSM | Axsome Therapeutics Inc | +0.8% | — | Unchanged |
| 13 | PTGX | Protagonist Therapeutics Inc | +0.7% | — | Unchanged |
| 14 | VRTX | Vertex Pharmaceuticals Inc | +0.7% | — | Unchanged |
| 15 | ✓ | Merus N V | +0.5% | +59.80% | Add |
| 16 | NUVL | Nuvalent Inc-a | +0.4% | NEW | New buy |
| 17 | INSM | Insmed Inc | +0.4% | -0.93% | Trim |
| 18 | 260 | Centessa Pharmaceuticals-adr | +0.4% | NEW | New buy |
| 19 | DYN | Dyne Therapeutics Inc | +0.4% | — | Unchanged |
| 20 | ALEC | Alector Inc | +0.3% | NEW | New buy |
| 21 | NBIX | Neurocrine Biosciences Inc | +0.2% | — | Unchanged |
| 22 | MREO | Mereo Biopharma Group Pl-adr | +0.2% | — | Unchanged |
| 23 | EYPT | Eyepoint Inc | +0.2% | +53.99% | Add |
| 24 | IDYA | Ideaya Biosciences Inc | +0.2% | +15.81% | Add |
| 25 | CLDX | Celldex Therapeutics Inc | +0.2% | — | Unchanged |
| 26 | ANNX | Annexon Inc | +0.1% | +16.78% | Add |
| 27 | KROS | Keros Therapeutics Inc | +0.1% | — | Unchanged |
| 28 | ✓ | Acelyrin Inc | +0.1% | NEW | New buy |
| 29 | XENE | Xenon Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 30 | ASND | Ascendis Pharma A/S | +0.1% | — | Unchanged |
| 31 | CRBP | Corbus Pharmaceuticals Holdi | +0.1% | +137.00% | Add |
| 32 | SMMT | Summit Therapeutics Inc | +0.1% | NEW | New buy |
| 33 | SWTXUSD | Springworks Therapeutics Inc | +0.1% | — | Unchanged |
| 34 | KURA | Kura Oncology Inc | +0.1% | — | Unchanged |
| 35 | SLN | Silence Therapeutics Plc-adr | +0.1% | — | Unchanged |
| 36 | QTTB | Q32 Bio Inc | +0.1% | NEW | New buy |
| 37 | CRL | Charles River Laboratories | +0.1% | -8.69% | Trim |
| 38 | SNDX | Syndax Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 39 | IRON | Disc Medicine Inc | +0.1% | — | Unchanged |
| 40 | NAMS | NewAmsterdam Pharma Company N.V. | +0.1% | — | Unchanged |
| 41 | LRMR | Larimar Therapeutics Inc | 0% | — | Unchanged |
| 42 | MDGL | Madrigal Pharmaceuticals Inc | 0% | — | Unchanged |
| 43 | SRPT | Sarepta Therapeutics Inc | -0.1% | EXIT | Sold out |
| 44 | CRNX | Crinetics Pharmaceuticals In | -0.1% | -46.64% | Trim |
| 45 | PLRX | Pliant Therapeutics Inc | -0.1% | EXIT | Sold out |
| 46 | IONS | Ionis Pharmaceuticals Inc | -0.3% | -51.22% | Trim |
| 47 | APGE | Apogee Therapeutics Inc | -0.4% | EXIT | Sold out |
| 48 | OCUL | Ocular Therapeutix Inc | -0.7% | EXIT | Sold out |
| 49 | ✓ | Insmed Inc | -1.4% | EXIT | Sold out |
| 50 | ✓ | Viking Therapeutics Inc | -1.5% | EXIT | Sold out |
According to official SEC Form 13F filings, Artia Global Partners LP reported a total U.S. public equity portfolio value of $541.9M across 44 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LLY, NVO, VKTX) accounted for 45.8% of total reported equity market value during Q3 2024.
Top New Position Initiated
RVMD
市值: $4.3M
Top Position Liquidated / Trimmed
ELI LILLY & CO
前期市值: $67.9M
During Q3 2024, Artia Global Partners LP's top holdings by market value included LLY (26.0%)、NVO (24.1%)、VKTX (9.2%). The largest single position, LLY, represented 26.0% of total portfolio value.
In Q3 2024, Artia Global Partners LP made 30 total portfolio adjustments, initiating 7 new buys, adding to 10 positions, trimming 4 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.